Introduction
Schizophrenia (SCZ) and related psychotic disorders are amongst the leading causes of global disease burden (McCutcheon, Reis Marques, & Howes, Reference McCutcheon, Reis Marques and Howes2020b). Current treatments are ineffective for many patients (Kaar, Natesan, McCutcheon, & Howes, Reference Kaar, Natesan, McCutcheon and Howes2020), highlighting the need to understand the neurobiology underlying psychosis to inform development of new drug treatments (Jauhar & Howes, Reference Jauhar and Howes2019; McCutcheon, Krystal, & Howes, Reference McCutcheon, Krystal and Howes2020a). Altered brain perfusion and metabolism have been implicated in the neurobiology of SCZ (Goozée, Handley, Kempton, & Dazzan, Reference Goozée, Handley, Kempton and Dazzan2014; Hill et al., Reference Hill, Mann, Laws, Stephenson, Nimmo-Smith and McKenna2004; Townsend et al., Reference Townsend, Pillinger, Selvaggi, Veronese, Turkheimer and Howes2022), initially with positron emission tomography (PET). PET studies with [18F]-fluorodeoxyglucose (FDG) and [15O]H2O reported hypometabolism and hypoperfusion in frontal, anterior cingulate, temporal and parietal cortices (Andreasen et al., Reference Andreasen, O'Leary, Flaum, Nopoulos, Watkins, Boles Ponto and Hichwa1997; Buchsbaum et al., Reference Buchsbaum, Ingvar, Kessler, Waters, Cappelletti, van Kammen and Sokoloff1982; Gur et al., Reference Gur, Mozley, Resnick, Mozley, Shtasel, Gallacher and Reivich1995). More recently, arterial spin labelling (ASL), utilizing magnetic resonance imaging (MRI), has been used to measure cerebral blood flow (CBF). Because of the well-established phenomenon of neuro-vascular coupling, measures of regional CBF are an indirect but highly sensitive signature of regional cellular activity. ASL studies in people with chronic SCZ, treated with antipsychotics, show reduced CBF in frontal, parietal and occipital regions and increased CBF in basal ganglia (Legind et al., Reference Legind, Broberg, Brouwer, Mandl, Ebdrup, Anhøj and Rostrup2019; Liu, Qiu, Constable, & Wexler, Reference Liu, Qiu, Constable and Wexler2012a; Oliveira et al., Reference Oliveira, Guimarães, Souza, Dos Santos, Machado-de-Sousa, Hallak and Leoni2018; Pinkham et al., Reference Pinkham, Loughead, Ruparel, Wu, Overton, Gur and Gur2011, Reference Pinkham, Liu, Lu, Kriegsman, Simpson and Tamminga2015), though the basal ganglia findings have not been consistently replicated (Ota et al., Reference Ota, Ishikawa, Sato, Okazaki, Maikusa, Hori and Kunugi2014; Zhu et al., Reference Zhu, Zhuo, Xu, Liu, Qin and Yu2017). Thus, there is evidence for cortical hypoperfusion in chronic SCZ, but it is unclear from these studies when this occurs in development of the disorder. Studies in clinical high risk for psychosis (CHR-P) individuals have reported increased CBF in basal ganglia and hippocampus (Allen et al., Reference Allen, Chaddock, Egerton, Howes, Bonoldi, Zelaya and McGuire2016, Reference Allen, Azis, Modinos, Bossong, Bonoldi, Samson and McGuire2018; Modinos et al., Reference Modinos, Şimşek, Azis, Bossong, Bonoldi, Samson and McGuire2018b). Increased hippocampal perfusion in CHR-P individuals has also been found with gadolinium-enhanced MRI (Schobel et al., Reference Schobel, Chaudhury, Khan, Paniagua, Styner, Asllani and Small2013). These findings indicate that CBF alterations may occur early in development of psychosis, though, because the majority of CHR-P subjects do not go on to develop psychosis, it is unclear how specific they are to psychosis. To date, only one study has investigated cerebral perfusion using ASL in people with first-episode psychosis (FEP) (Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018). This study found increased perfusion in basal ganglia and reduced CBF in frontal cortex in people with FEP, all of whom were taking antipsychotic medication.
However, antipsychotics have effects on brain metabolism and CBF (Goozée et al., Reference Goozée, Handley, Kempton and Dazzan2014; Hawkins et al., Reference Hawkins, Wood, Vernon, Bertolino, Sambataro, Dukart and Mehta2018; Mehta et al., Reference Mehta, McGowan, Lawrence, Aitken, Montgomery and Grasby2003; Miller et al., Reference Miller, Andreasen, O'Leary, Rezai, Watkins, Ponto and Hichwa1997; Turkheimer et al., Reference Turkheimer, Selvaggi, Mehta, Veronese, Zelaya, Dazzan and Vernon2020), with evidence from preclinical models (Sander et al., Reference Sander, Hooker, Catana, Normandin, Alpert, Knudsen and Mandeville2013, Reference Sander, Mandeville, Wey, Catana, Hooker and Rosen2019; Sander, Hooker, Catana, Rosen, & Mandeville, Reference Sander, Hooker, Catana, Rosen and Mandeville2016; Viviani, Graf, Wiegers, & Abler, Reference Viviani, Graf, Wiegers and Abler2013) and experimental medicine studies in healthy individuals (Hawkins et al., Reference Hawkins, Wood, Vernon, Bertolino, Sambataro, Dukart and Mehta2018; Selvaggi et al., Reference Selvaggi, Hawkins, Dipasquale, Rizzo, Bertolino, Dukart and Mehta2019; Viviani et al., Reference Viviani, Graf, Wiegers and Abler2013) suggesting that antipsychotics increase CBF in the basal ganglia with a mechanism possibly mediated by D2 receptors (Sander et al., Reference Sander, Hooker, Catana, Normandin, Alpert, Knudsen and Mandeville2013; Selvaggi et al., Reference Selvaggi, Hawkins, Dipasquale, Rizzo, Bertolino, Dukart and Mehta2019). The effect of antipsychotics on cortical perfusion is even less understood. Studies using PET and single photon emission computed tomography (SPECT) found consistently reduced perfusion and metabolism in the frontal cortex in both medicated and unmedicated patients with SCZ (Makarić et al., Reference Makarić, Bošnjak, Kekin, Jelacic, Haupert, Đuran and Rojnić Kuzman2017; Molina et al., Reference Molina, Sanz, Reig, Martínez, Sarramea, Luque and Desco2005). Viviani et al. (Reference Viviani, Graf, Wiegers and Abler2013) found decreased cortical perfusion after amisulpride administration in healthy volunteers. It is therefore unclear if previous findings in FEP were confounded by antipsychotic treatment and what is the extent of the interaction between antipsychotic effects and pathophysiology. Thus, we aimed to determine if CBF is altered in people in their first episode of psychosis who are free from antipsychotic medication (baseline study). Based on prior studies in FEP and subjects at CHR-P, we hypothesized that antipsychotic-free people with FEP would show lower absolute CBF in the frontal cortex while keeping CBF in the striatum within physiological ranges.
Moreover, while previous cross-sectional investigations have shown associations between altered CBF and severity of psychotic symptoms in SCZ (Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018; Pinkham et al., Reference Pinkham, Loughead, Ruparel, Wu, Overton, Gur and Gur2011), it is unknown if brain perfusion before treatment is associated with subsequent symptomatic improvement with antipsychotic treatment. Thus, we aimed to explore this association in a prospective study of patients who went on to receive antipsychotic treatment (follow-up study). To summarize, we adopted a partially nested two-study design to (i) investigate differences in brain perfusion in FEP prior to start antipsychotic treatment (baseline study) and (ii) identify brain perfusion markers of treatment response possibly unbiased by antipsychotic effects on CBF.
Materials and methods
Study participants
Study participants were recruited from FEP teams within South London and Maudsley NHS Foundation Trust (Fusar-Poli et al., Reference Fusar-Poli, Lai, Di Forti, Iacoponi, Thornicroft, McGuire and Jauhar2020) and Central and West London NHS Trust. All participants provided informed written consent. For both groups' exclusion criteria were history of head trauma, dependence on illicit drugs, any significant medical co-morbidity (minor illnesses such as seasonal allergies were permitted) and contra-indication to MRI scanning.
Baseline study
Inclusion criteria for the patient group were: psychotic disorder according to ICD-10 criteria (World Health Organization, 2004) in first episode of illness. Age and gender-matched healthy volunteers were recruited through local advertisement from the same geographical areas. Inclusion criteria for healthy controls (HCs) were: no personal history of psychiatric illness [assessed using the Structured Clinical Interview for the DSM (First, Reference First, Cautin and Lilienfeld2014)] and no history of psychotropic medication use. All patients were antipsychotic-naïve or antipsychotic-free for at least 6 weeks for oral antipsychotics or 6 months for depot antipsychotics (Jauhar et al., Reference Jauhar, Veronese, Nour, Rogdaki, Hathway, Turkheimer and Howes2019; Leucht et al., Reference Leucht, Winter-van Rossum, Heres, Arango, Fleischhacker, Glenthøj and Sommer2015). The sample included nine antipsychotic-naïve and 12 antipsychotic-free patients. All but one patient included in the baseline study was not taking other psychotropic medication (i.e. antidepressants, mood stabilizers, benzodiazepines) at the time of MRI scan. Only one patient was taking antidepressant medication (sertraline) at the time of MRI scan (Viviani, Abler, Seeringer, & Stingl, Reference Viviani, Abler, Seeringer and Stingl2012).
Follow-up study
Inclusion criteria for the patient group were: psychotic disorder according to ICD-10 criteria (World Health Organization, 2004); in first episode of illness; and antipsychotic-free or -naïve or minimally treated [taking antipsychotics at minimal effective dose for less than 2 weeks (Agid, Kapur, Arenovich, & Zipursky, Reference Agid, Kapur, Arenovich and Zipursky2003; Levine & Leucht, Reference Levine and Leucht2012)]. All patients were clinically assessed at baseline and reassessed after taking antipsychotic treatment, at a therapeutic dose as specified in the Maudsley Prescribing Guidelines (Taylor, Barnes, & Young, Reference Taylor, Barnes and Young2018), for a minimum of 4 weeks. All patients were in stable treatment at follow-up after titration. Clinical measures were rated at baseline and follow-up using the Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, Reference Kay, Fiszbein and Opler1987). Patients received follow-up for at least 6 months to determine if there had been a subsequent response in patients who showed non-response at 4 weeks (duration to follow-up in months 24.73 ± 16.89). Subjects with psychosis were classified by antipsychotic exposure as antipsychotic-naïve, antipsychotic-free [prior oral antipsychotic medication but free of treatment for at least 6 week (oral) or 6 months (depot, if relevant)] or minimally treated (taking antipsychotic medication for 2 weeks or less) (Jauhar et al., Reference Jauhar, Veronese, Nour, Rogdaki, Hathway, Turkheimer and Howes2019; Leucht et al., Reference Leucht, Winter-van Rossum, Heres, Arango, Fleischhacker, Glenthøj and Sommer2015). The sample included seven antipsychotic-naïve, four antipsychotic-free and three people minimally treated with antipsychotics.
MRI acquisition and pre-processing
MRI acquisition
Scans were acquired using a GE MR750 3-T scanner and a 12-channel head coil. A T1-weighted MPRAGE scan was also acquired (FOV = 260 mm; echo time = 2.8 ms; repetition time = 6.98 ms; 256 × 256 matrix; slice thickness = 1.2 mm, flip angle = 11) for normalization purposes. A T2-weighted image (FOV = 240 mm; echo time = 54.68 ms; repetition time = 4380 ms; 320 × 320 matrix; slice thickness = 4 mm) was also acquired and used for the pre-processing of ASL images (see below). ASL data were acquired using a pseudo-continuous arterial spin labelling sequence (PCASL). Four control-label pairs were used (labelling time = 1525 ms; post labelling delay = 1500 ms). Images were read with a 3D Fast-Spin echo stack of spirals scheme, consisting of eight inter-leaved spiral arms, 512 points per arm and 60 slice-locations of 3 mm thickness. The raw spatial resolution of the perfusion sensitive images was approximately 3.6 mm in plane and 3 mm through plane; and the data points were re-gridded to a rectangular matrix prior to Fourier transformation and written with a voxel size of 1 × 1 × 3 mm (no gap). The sequence had background suppression for optimum reduction of the static tissue signal (for further details, see online Supplementary materials). A proton density (PD) image was also acquired over 48 s using the same acquisition parameters.
Pre-processing
PD images were used to obtain quantification of absolute CBF in standard physiological units (ml blood/100 g tissue/min) using the formula suggested in the recent ASL consensus paper (Alsop et al., Reference Alsop, Detre, Golay, Günther, Hendrikse, Hernandez-Garcia and Zaharchuk2015). The unified segmentation algorithm in SPM12 (Ashburner & Friston, Reference Ashburner and Friston2005) was used to create grey matter, white matter and cerebrospinal fluid (CSF) images from each T1-weighted image and to create a set of flow fields to later transform each subject's T1-weighted and ASL data into standard space. The T2-weighted images were co-registered to the T1-weighted images. Each raw PD image was then co-registered to the T2 image. The parameters for this transformation were then applied to the CBF maps (as they were already in alignment with the PD image) prior to their normalization. The addition of these two co-registration steps helped us to achieve a better alignment between CBF and T1-weighted images which prevented from distortions during normalization. Images were resampled to 2 mm isotropic voxels and normalized into a standard space (Montreal Neurological Institute, MNI). Finally, the normalized CBF maps were smoothed using a 6 mm full width at half maximum (FWHM) kernel. Normalized T1-weighted images were also smoothed using a 6 mm FWHM kernel.
Statistical analysis
Demographics
Demographic characteristics (i.e. age, gender) were compared between FEP and HC using χ2 or independent sample t tests for categorical and continuous data respectively.
Region of interest (ROI) analysis
Absolute CBF values in the whole grey matter and in each ROI were extracted using spatially normalized to individual grey matter images and the WFU-Pickatlas ROIs with the MarsBar toolbox (http://marsbar.sourceforge.net). Based on previous findings (Allen et al., Reference Allen, Chaddock, Egerton, Howes, Bonoldi, Zelaya and McGuire2016; Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018), the following bilateral ROIs were selected as our primary ROIs: the frontal cortex (size = 61 104 mm), the hippocampus (size = 15 024 mm) and the striatum (size = 36 816 mm). For comparisons with previous investigations (Allen et al., Reference Allen, Chaddock, Egerton, Howes, Bonoldi, Zelaya and McGuire2016; Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018), we also explored differences between FEP and HC in relative-to-global-perfusion CBF (relative CBF). For each ROI a linear regression model was performed with absolute CBF in the ROI as the dependent variable and global grey matter CBF as the independent variable. For each linear regression in each ROI unstandardized residuals were computed.
To test our primary hypothesis that FEP would show reduced absolute CBF in frontal cortex and increased CBF in striatum and hippocampus, a repeated measure analysis of variance (ANOVA) was used with ‘ROI’ as the within-subject factor and ‘GROUP’ as the between-subject factor. Tukey HSD test has been used for post-hoc pairwise comparison. An independent sample t test was used to test absolute CBF in the whole grey matter to determine if there was a global group difference in CBF. Cohen's d has been computed to obtain estimates of effect size. To test differences in relative-to-global CBF, absolute CBF unstandardized residual against global grey matter CBF were entered as dependent variables in a repeated measure ANOVA with ‘ROI’ as within-subject variable and ‘GROUP’ as between-subjects variable. Tukey HSD has been used for post-hoc pairwise comparison.
Voxel-wise analysis
Differences in absolute CBF were also tested in whole-brain voxel-wise analyses. Based on recent recommendations (Eklund, Nichols, & Knutsson, Reference Eklund, Nichols and Knutsson2016), we performed non-parametric analysis as implemented in FSL randomise (Winkler, Ridgway, Webster, Smith, & Nichols, Reference Winkler, Ridgway, Webster, Smith and Nichols2014) and threshold-free cluster enhancement (TFCE) (Smith & Nichols, Reference Smith and Nichols2009) with 5000 permutations to create a non-parametric null distribution and calculate a 5% significant threshold. We also tested relative-to-global-perfusion CBF differences between FEP and HC in voxel-wise analysis using FSL randomise by including global grey matter CBF as a nuisance covariate in the model. An independent sample t test was used to test differences in intracranial volume (ICV) between FEP and HC.
Structural analysis
In order to check whether results could be influenced by differences in grey matter volume differences between FEP and HC, standard voxel-based morphometry (VBM) analysis as implemented in SPM was performed on pre-processed T1-weighted images to determine if there were volumetric differences between groups. Voxel-wise independent sample t test as implemented in SPM were performed to assess differences in grey matter volume between FEP and controls. Grey matter, white matter and CSF images of each subject were combined to obtain estimates of total ICV. In addition, T1-weighted images were processed using FreeSurfer (version 7.1.1, http://surfer.nmr.harvard.edu) image analysis suite to produce measures of cortical thickness estimates using the FreeSurfer automated brain segmentation process (recon-all) (Fischl & Dale, Reference Fischl and Dale2000; Salat et al., Reference Salat, Buckner, Snyder, Greve, Desikan, Busa and Fischl2004). An FWHM Gaussian kernel of 10 mm was applied. Vertex-wide independent sample t test was performed for both left and right hemisphere to assess differences in cortical thickness between FEP and controls. Both FEP > HC and FEP < HC contrast were analysed. Cluster-level correction for multiple comparison was implemented with −log 10(p)value = 3 as cluster-defining threshold and alpha = 0.05 (Greve & Fischl, Reference Greve and Fischl2018).
Correlation with PANSS change
Percentage changes in PANSS was calculated, adjusting for minimum scores (% change in total PANSS = [((baseline score – 30) − (follow-up score – 30))/(baseline score − 30)] × 100) (Leucht et al., Reference Leucht, Kane, Kissling, Hamann, Etschel and Engel2005).
To explore the association between baseline CBF and improvement in symptoms, linear regression analysis was performed between both baseline absolute and relative-to-global-CBF values from our primary ROIs and percentage change in total PANSS. For each linear regression model Bonferroni correction was applied for the number of ROI tested (alpha = 0.05/3 = 0.016). For all linear regression models Mahalanobis distance and Cook's distance were computed to examine the presence of multivariate outliers and to estimate the presence of highly influential data points. To identify multivariate outliers, Mahalanobis distance values were compared to a χ2 distribution with degrees of freedom equal to the number of variables (two in this case) with p = 0.001 (Finch, Reference Finch2012). Any data point with Cook's distance higher than 1 was considered a highly influential outlier and excluded from the analysis as recommended [see Cook & Weisberg, Reference Cook and Weisberg1982]. To further test the robustness of our analysis reducing the effect of extreme observations, we used the bias-corrected accelerated bootstrap technique with 10 000 resamples (Efron & Tibshirani, Reference Efron and Tibshirani1986).
Results
Baseline study
Demographics
Twenty-one people with FEP [mean age ± standard deviation (s.d.), 24.85 ± 3.85, three female] and 22 HC (23.45 ± 3.21, eight female) were included in the baseline study. HC and FEP groups did not significantly differ in age (t = 1.29, p = 0.3) or gender (χ2 = 2.8, p = 0.1) (Table 1).
Summary of demographic and clinical characteristics of the baseline study sample
Absolute CBF
Absolute whole brain CBF was significantly lower in FEP (mean ± s.d., 27.642 ± 59.52) as compared to controls (mean ± s.d., 32.334 ± 43.75) (t = −2.94, df = 41, p = 0.005, Cohen's d = 0.89). Results did not change after removal of the subject receiving antidepressant at the time of the scan (p < 0.001).
There was a significant main effect of ‘GROUP’ (F = 4.74, p = 0.035) and a significant ‘ROI’ × ‘GROUP’ interaction (F = 3.89, p = 0.032 after Greenhouse–Geisser correction) on absolute CBF. Tukey HSD post hoc test revealed significantly lower absolute CBF in the frontal cortex in FEP as compared to HC (t = −2.75, df = 41, p = 0.009, Cohen's d = 0.84) with no statistically significant differences between FEP and HC in the hippocampus (t = −1.5, df = 41, p = 0.13) or striatum (t = −1.4, df = 41, p = 0.1). Results did not change after removal of the subject receiving antidepressant at the time of the scan (p < 0.001). Figure 1 shows absolute CBF values in the three ROIs (i.e. frontal cortex, hippocampus and striatum).
Absolute CBF in the selected a priori ROIs. There were significant main effects of group and ROI, and a significant group*ROI interaction (p = 0.032, Greenhouse-Geisser correction). Post-hoc testing showed that CBF was significantly lower in the frontal cortex (Cohen's d = 0.84, p = 0.009) but not the other regions in patients with FEP relative to controls. FEP = first episode psychosis, HC = healthy controls. Asterisks (*) indicated significant tests. Bars indicate 95% confidence intervals.
We conducted an exploratory analysis separating the patients into antipsychotic-naïve and antipsychotic-free sub-groups. This shows that CBF levels are similar in antipsychotic-naïve and antipsychotic-free sub-groups (see online Supplementary materials).
Relative-to-global CBF
There was a trend towards a significant main effect of ‘GROUP’ (F = 3.9, p = 0.054), but no significant main effect of ‘ROI’ (p = 0.85) or significant ‘ROI × GROUP’ interaction (p = 0.23) on relative CBF.
CBF whole-brain voxel-wise analysis
Figure 2 shows whole-brain voxel-wise differences (p < 0.05, TFCE-corrected) between FEP and HC. The direct voxel-wise comparison revealed significantly lower CBF in FEP compared to HC in widespread cortical areas including frontal, parietal and occipital areas. The opposite contrast (i.e. HC < FEP) did not reveal any significant clusters.
Brain sections showing significantly lower absolute CBF in FEP relative to HC in frontal, parietal and occipital cortex (TFCE corrected clusters). Colorbar indicates t-statistics.
Whole brain voxel-wise analysis of relative-to-global CBF did not reveal any TFCE-corrected cluster in either FEP > HC or FEP < HC contrasts.
Structural analysis
FEP and HC did not differ in total grey matter volume (t = −1.8, df = 41, p = 0.08) or total ICV (t = 0.95, df = 41, p = 0.96). Voxel-wise VBM analysis did not reveal any significant differences in grey matter volume between FEP and HC. FreeSurfer analysis did not reveal any significant cluster of cortical thickness differences between FEP and HC.
Follow-up study
Demographics
Fourteen FEP (23.85 ± 3.77, four female) were included in the follow-up study. Eleven patients also took part in the baseline study (Table 2).
Summary of demographics and clinical characteristics of the follow-up study sample
Correlations between baseline CBF and PANSS change
There were no significant associations between absolute CBF extracted from the ROIs and percentage change in total PANSS score (p > 0.32). However, relative-to-global CBF in the frontal cortex correlated positively with percentage change in total PANSS (Fig. 3; r = 0.67, p = 0.008). In all linear regression models, none of the data points were identified as influential outliers (all Cook's distances < 1) or multivariate outliers (all Mahalanobis distances p > 0.001). Results were retained after applying bias-corrected accelerated bootstrap technique with 10 000 resamples (bootstrapped p = 0.05). In addition, Spearman rank correlations yielded similar results to linear regression analysis (Spearman rho = 0.574, p = 0.032).
Scatterplots showing significant correlations between relative-to-global frontal CBF at baseline and percentage improvement in total PANSS with subsequent treatment (r = 0.57, p = 0.05).
Discussion
We found absolute CBF was significantly lower in frontal cortex but not striatum or hippocampus in people with FEP free of antipsychotic medication. Our whole brain analyses found significantly lower perfusion in the patients in additional cortical areas, including the parietal and occipital cortices.
Lower perfusion and metabolism of frontal cortex at rest is a replicated finding in chronic SCZ (Bullmore et al., Reference Bullmore, Brammer, Williams, Curtis, McGuire, Morris and Sharma1999; Weinberger & Berman, Reference Weinberger and Berman1988) demonstrated using various neuroimaging techniques including SPECT, [18F]-FDG and [15O]-H2O PET, blood oxygen level dependent (BOLD) signal [i.e. functional magnetic resonance imaging (fMRI)] and recently with ASL (Hill et al., Reference Hill, Mann, Laws, Stephenson, Nimmo-Smith and McKenna2004; Kindler et al., Reference Kindler, Jann, Homan, Hauf, Walther, Strik and Hubl2015). Interestingly previous studies using PET and SPECT in unmedicated FEP revealed reduced cortical perfusion and metabolism (Brewer et al., Reference Brewer, Yücel, Harrison, McGorry, Olver, Egan and Pantelis2007; Makarić et al., Reference Makarić, Bošnjak, Kekin, Jelacic, Haupert, Đuran and Rojnić Kuzman2017; Molina et al., Reference Molina, Sanz, Reig, Martínez, Sarramea, Luque and Desco2005). Our results corroborate and extend this evidence by showing the existence of lower frontal cortical absolute perfusion in FEP without the potential confound of antipsychotic treatment using MRI. In addition, our exploratory whole brain analyses indicate cortical hypoperfusion extends beyond the frontal cortex, including both parietal and occipital cortices. This extends evidence that the function of these regions is altered during cognitive tasks in SCZ (Calderone et al., Reference Calderone, Martinez, Zemon, Hoptman, Hu, Watkins and Butler2013; Hahn, Robinson, Leonard, Luck, & Gold, Reference Hahn, Robinson, Leonard, Luck and Gold2018; Weiss et al., Reference Weiss, Ellis, Roffman, Stufflebeam, Hamalainen, Duff and Schacter2009) to show perfusion is also altered early in illness course. In contrast to findings in antipsychotic-treated patients and people at clinical risk of psychosis (Allen et al., Reference Allen, Azis, Modinos, Bossong, Bonoldi, Samson and McGuire2018; Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018), we found no significant difference in relative-to-global CBF in the striatum or hippocampus relative to controls. When our results are considered alongside preclinical (Mandeville et al., Reference Mandeville, Sander, Jenkins, Hooker, Catana, Vanduffel and Normandin2013; Sander et al., Reference Sander, Hooker, Catana, Normandin, Alpert, Knudsen and Mandeville2013, Reference Sander, Mandeville, Wey, Catana, Hooker and Rosen2019) and clinical (Handley et al., Reference Handley, Zelaya, Reinders, Marques, Mehta, O'Gorman and Dazzan2013; Selvaggi et al., Reference Selvaggi, Hawkins, Dipasquale, Rizzo, Bertolino, Dukart and Mehta2019; Shcherbinin et al., Reference Shcherbinin, Doyle, Zelaya, de Simoni, Mehta and Schwarz2015; Viviani et al., Reference Viviani, Graf, Wiegers and Abler2013) evidence that antipsychotics increase striatal perfusion, with a mechanism possibly mediated by D2 receptors (Selvaggi et al., Reference Selvaggi, Hawkins, Dipasquale, Rizzo, Bertolino, Dukart and Mehta2019), this could indicate that previous evidence of higher striatal CBF in people with SCZ taking antipsychotics might be explained by D2 receptors blockade.
Longitudinal studies are required to confirm preliminarily evidence (Goozée et al., Reference Goozée, Handley, Kempton and Dazzan2014) suggesting that treatment does increase striatal perfusion in patients.
We did not find any differences in hippocampus in either absolute or relative-to-global perfusion, in contrast to findings in people at clinical risk of psychosis. Taken with our findings in frontal cortex, this could suggest that there is progression of pathophysiological alterations from the hippocampus prior to the onset of psychosis to the frontal cortex with the development of illness. However, it should be recognized that not all subjects at clinical risk develop psychosis and longitudinal studies with repeated scanning are required to test if there are changes in hypoperfusion during the development of psychosis.
Relative-to-global CBF in the frontal cortex at presentation explained approximately 40% of the variance in subsequent response to antipsychotic treatment, such that patients with higher relative-to-global CBF showed higher symptom improvement with treatment. These results extend prior evidence that response to antipsychotic treatment in FEP is associated with functional connectivity (Sarpal et al., Reference Sarpal, Argyelan, Robinson, Szeszko, Karlsgodt, John and Malhotra2016), D2/3 availability (Wulff et al., Reference Wulff, Pinborg, Svarer, Jensen, Nielsen, Allerup and Glenthøj2015), and dopamine synthesis capacity (Jauhar et al., Reference Jauhar, Veronese, Nour, Rogdaki, Hathway, Turkheimer and Howes2019) to suggest that relative frontal perfusion could potentially contribute to a biomarker for antipsychotic response in FEP (Veronese et al., Reference Veronese, Santangelo, Jauhar, D'Ambrosio, Demjaha, Salimbeni and Howes2021). We did not find correlations between relative-to-global CBF in the striatum and hippocampus and PANSS change. However, given the lower CBF in a number of cortical regions in patients, it might be possible that cortical regions other than the frontal cortex are also linked to treatment response but we were underpowered to detect these relationships. We did not find correlations between absolute CBF and PANSS change, suggesting that changes in local perfusion relative to whole brain perfusion are best able to capture variability in clinical response. We found that antipsychotic-free FEP show lower absolute CBF in cortical regions but no significant difference in relative-to-global CBF. Treatment response was associated with relative-to-global frontal CBF but not with absolute CBF. The absence of group differences in relative-to-global CBF are consistent with our whole brain findings that indicate that there is lower absolute CBF in other cortical regions, mainly driven by lower CBF in parietal and occipital cortices as compared with controls. On the other hand, subcortical CBF (i.e. striatal and hippocampal) seems to be unaltered in patients relative to controls (see Bayes factor testing in online Supplementary materials). Thus, taken together, these findings suggest an imbalance between cortical and subcortical blood flow early in SCZ. The association between relative-to-global CBF (but not absolute CBF) with treatment response might seem counterintuitive. However, this finding might be less difficult to interpret considering the direct association between the two variables. Patients with larger positive improvement in symptoms (i.e. greater symptoms reduction) were those with relatively lower alterations in frontal CBF as compared with the rest of the cortex (i.e. higher relative-to-global frontal CBF), suggesting that patients with more marked frontal hypofunction are less responsive to treatment with D2 blockers. This extends other evidence of frontal dysfunction in patients whose illness does not respond to D2 blockers (Mouchlianitis, McCutcheon, & Howes, Reference Mouchlianitis, McCutcheon and Howes2016; Potkin et al., Reference Potkin, Kane, Correll, Lindenmayer, Agid, Marder and Howes2020). This interpretation is coherent with recent reports indicating neurovascular uncoupling in brain regions such the frontal cortex in SCZ (Sukumar, Sabesan, Anazodo, & Palaniyappan, Reference Sukumar, Sabesan, Anazodo and Palaniyappan2020).
Strengths and limitations
Strengths of this study include the inclusion of people with FEP free from antipsychotic medication, and longitudinal measures in FEP patients. A methodological strength of the study is the evaluation of both absolute and relative-to-global CBF. Previous studies in CHR-P and FEP have used one metric without reporting the other (Allen et al., Reference Allen, Azis, Modinos, Bossong, Bonoldi, Samson and McGuire2018; Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018; Modinos et al., Reference Modinos, Şimşek, Azis, Bossong, Bonoldi, Samson and McGuire2018b). However, our results suggest that antipsychotic-free FEP show different pattern of alteration in absolute and relative-to-global CBF. Therefore, we advise that future studies should include both metrics to facilitate comparisons. Previous works testing CBF differences in chronic SCZ as compared with HCs using ASL have shown variability in grey matter perfusion across individuals (Chen et al., Reference Chen, Xue, Yang, Wang, Xu, Wen and Wei2022; Parkes, Rashid, Chard, & Tofts, Reference Parkes, Rashid, Chard and Tofts2004; Pinkham et al., Reference Pinkham, Loughead, Ruparel, Wu, Overton, Gur and Gur2011; Wang et al., Reference Wang, Li, Roc, Alsop, Tang, Butler and Detre2004). In our study we used a 3D PCASL with background suppression which offers a non-invasive, efficient and highly reproducible tool to investigate brain perfusion as compared with other ASL methods (Alsop et al., Reference Alsop, Detre, Golay, Günther, Hendrikse, Hernandez-Garcia and Zaharchuk2015; Chen, Wang, & Detre, Reference Chen, Wang and Detre2011). PCASL sequences have shown higher test–retest reliability as compared with other MRI sequences (such as BOLD task or resting state fMRI) used to identify biomarkers in psychosis (Holiga et al., Reference Holiga, Sambataro, Luzy, Greig, Sarkar, Renken and Dukart2018). In addition PCASL has shown good between- and within-subjects reliability [Intraclass coefficient (ICC) range: 0.63–0.83; (Holiga et al., Reference Holiga, Sambataro, Luzy, Greig, Sarkar, Renken and Dukart2018)], and comparable with PET [18F]-DOPA [ICC range: 0.42–0.94; (Egerton, Demjaha, McGuire, Mehta, & Howes, Reference Egerton, Demjaha, McGuire, Mehta and Howes2010)], which has been proposed as a potential biomarker for treatment stratification in psychosis (Veronese et al., Reference Veronese, Santangelo, Jauhar, D'Ambrosio, Demjaha, Salimbeni and Howes2021). We obtained absolute CBF values on average of 40–50 ml/100 g tissue/min in grey matter in healthy volunteers which are at the lower range of previous investigations using pulsed ASL and/or other scanner manufacturers (Alsop et al., Reference Alsop, Detre, Golay, Günther, Hendrikse, Hernandez-Garcia and Zaharchuk2015). In our study we used a post-labelling approach and background suppression protocol that was slightly slower than the one recommended by the ASL white paper (Alsop et al., Reference Alsop, Detre, Golay, Günther, Hendrikse, Hernandez-Garcia and Zaharchuk2015), which could account for the slightly lower CBF values we obtained. However, we did not find artefactual hyper-perfusion regions in our analysis, suggesting that the post-labelling delay is not having a major effect on data quality. One potential issue in the imaging analysis could be the influence of partial volume effects given structural brain alterations in FEP (Brugger & Howes, Reference Brugger and Howes2017). However, we did not find group differences in grey matter volume, total ICV and cortical thickness, suggesting that partial volume effects are unlikely to explain our results, although we cannot completely rule out a contribution of partial volume effects to our findings. Demographic heterogeneity of the sample is thought to be an important factor contributing to variability across individuals. In particular age and gender have been strongly associated with CBF variability (Liu et al., Reference Liu, Zhu, Feinberg, Guenther, Gregori, Weiner and Schuff2012b; Viviani et al., Reference Viviani, Sim, Lo, Richter, Haffer, Osterfeld and Beschoner2009; Zhang et al., Reference Zhang, Gordon, Ma, Chi, Gomar, Peng and Goldberg2018). The groups were very similar in mean age and gender distribution. Nevertheless, to check for any influence of these, we conducted further analyses including these as covariates. Our findings remained essentially unchanged when gender and age were added as covariate of no interest (see online Supplementary materials), suggesting these are not influencing our findings. Body-mass index, caffeine intake or nicotine consumption immediately prior to scanning could be other sources of variability. In common with prior studies in psychosis (Davies et al., Reference Davies, Paloyelis, Rutigliano, Cappucciati, De Micheli, Ramella-Cravaro and Fusar-Poli2019; Modinos et al., Reference Modinos, Egerton, McMullen, McLaughlin, Kumari, Barker and Zelaya2018a; Overton, Bhagwat, Viviano, Jacobs, & Voineskos, Reference Overton, Bhagwat, Viviano, Jacobs and Voineskos2020; Schneider et al., Reference Schneider, Michels, Hartmann-Riemer, Burrer, Tobler, Stämpfli and Kaiser2019), we did not control for these. However, the two groups were matched by smoking status, alcohol intake and substance use, which suggests that both caffeine intake and nicotine consumption might be similar between groups. Nevertheless, we cannot exclude group differences in use of these substances influencing our findings and further studies matching for intake on these would be useful.
In addition, it should be recognized that the frontal ROI is larger than the hippocampal and striatal ROIs. This may result in a higher signal-to-noise ratio (SNR) for the frontal region over these other regions, and consequently greater sensitivity to detect group differences. However, SNR estimates and sensitivity analyses (see online Supplementary materials) both suggest that it is unlikely that ROI size has affected our results.
Furthermore, in our follow-up study patients were treated in a naturalistic design. Thus, our findings do not provide information about the specific effects of antipsychotic treatment. Finally, although the baseline study constituted a larger cohort than that previously reported in FEP (Kindler et al., Reference Kindler, Schultze-Lutter, Hauf, Dierks, Federspiel, Walther and Hubl2018), given the relatively modest sample size, further studies are needed to test the generalisability of our findings to other cohorts and settings.
Implications and future directions
Frontal dysfunction is one of the key mechanisms thought to contribute to the pathophysiology of psychosis (Howes & Murray, Reference Howes and Murray2014; McCutcheon et al. Reference McCutcheon, Reis Marques and Howes2020b; Weinberger & Berman, Reference Weinberger and Berman1988). Our finding that frontal hypoperfusion is present early in the development of the disorder and in unmedicated patients is consistent with these models and other markers of frontal hypofunction in SCZ (Howes and McCutcheon, Reference Howes and McCutcheon2017; Onwordi et al., Reference Onwordi, Halff, Whitehurst, Mansur, Cotel, Wells and Howes2020; Osimo, Beck, Reis Marques, and Howes, Reference Osimo, Beck, Reis Marques and Howes2019). In addition, given the close link between CBF and brain metabolism (Riederer et al., Reference Riederer, Bohn, Preibisch, Wiedemann, Zimmer, Alexopoulos and Förster2018), our results are in line with the evidence of increased lactate levels and pH (Dogan, Yuksel, Du, Chouinard, & Öngür, Reference Dogan, Yuksel, Du, Chouinard and Öngür2018; Du et al., Reference Du, Cooper, Thida, Sehovic, Lukas, Cohen and Ongür2014) and mitochondrial dysfunction in SCZ (Prince, Blennow, Gottfries, Karlsson, & Oreland, Reference Prince, Blennow, Gottfries, Karlsson and Oreland1999; Rajasekaran, Venkatasubramanian, Berk, & Debnath, Reference Rajasekaran, Venkatasubramanian, Berk and Debnath2015) suggesting that altered brain oxidative capacity could be the pathophysiological substrate underlying abnormal brain function in psychosis. In addition, our results suggest alterations in brain perfusion at presentation are associated with subsequent antipsychotic response. These findings suggest that brain perfusion could be used to help predict future response.
Previous evidence suggested antipsychotics may normalize brain metabolism (Buchsbaum et al., Reference Buchsbaum, Haznedar, Newmark, Chu, Dusi, Entis and Wolkin2009), however recently some authors have proposed that this normalization might not be sustainable in some patients (Turkheimer et al., Reference Turkheimer, Selvaggi, Mehta, Veronese, Zelaya, Dazzan and Vernon2020). Future longitudinal studies are therefore needed to understand the effect of antipsychotic treatment on brain metabolism in psychosis.
Conclusions
Our results provide evidence for lower frontal perfusion in FEP without the potential confound of antipsychotic treatment. In addition, relative CBF in frontal cortex at baseline is associated with subsequent antipsychotic response. These findings indicate there is cortical hypofunction early in the course of psychosis.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/S0033291722002288.
Acknowledgements
We thank the patients who took part in this study, as well as the clinical teams within SLaM and CNWL who facilitated recruitment. We also thank the Guest editor and the reviewers for the critical in-depth reading of this manuscript and the very constructive comments.
Financial support
This study was funded by Medical Research Council-UK (no. MC_U120097115), Maudsley Charity (no. 666) and Wellcome Trust (no. 094849/Z/10/Z) grants to Prof. Howes. This paper represents independent research part funded by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London that support P. S., S. J., F. Z., M. V., M. A. M. and O. D. H. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. P. S. is supported by a Ph.D. studentship jointly funded by the NIHR-BRC at SLaM and the Department of Neuroimaging, King's College London. S. J. is funded by a JMAS Sim Fellowship from the Royal College of Physicians, Edinburgh.
Conflict of interest
S. J. has received honoraria for educational talks given for Sunovion. K. C. L. has received funding for educational talks S. J. has given. In the past 3 years M. A. M. has acted as an advisory board member for Lundbeck and Forum Pharmaceuticals. He also received research funding from Lundbeck, Takeda and Johnson & Johnson. Dr Howes is a part-time employee of Lundbeck and has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Recordati and Roche. Dr Howes has a patent for the use of dopaminergic imaging. No other conflict of interested are disclosed.
Ethical standards
The study was approved by the East of England-Cambridge East NHS Research Ethics Committee.
Open access
